SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Safe & Green Holdings Corp. is a design and construction services company, which engages in the provision of code engineered cargo shipping containers. It operates through the following segments: Construction, Medical, Development, and Corporate and Support. The Construction Services segment includes the manufacturing of unit SG ECHO and other modules projects. The Medical segment consists of joint venture COVID-19 laboratory operations. The Development segment focuses on real property development. The Corporate and Support segment includes general corporate expenses such as the executive office, corporate finance, accounting, audit, tax, human resources, risk management, information technology, marketing, and legal groups, corporate overhead, and other items not allocated to any of the company's other segments. The company was founded on December 29, 1993 and is headquartered in Miami, FL.

Safe & Green Holdings Corp

Safe & Green Holdings is trending due to high short interest and a strategic shift towards integrated energy solutions, sparking discussions of a potential short squeeze. The community is debating the stock's volatility, with some urging others to hold strong while others are wary of a potential pump and dump. Bullish investors are comparing it to previous squeeze events.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia's performance post-earnings is sparking mixed reactions, with some questioning if the AI hype is sustainable as the stock struggles to hold gains despite positive results. The community is debating potential accounting issues and the concentration of revenue among a few key customers, while others see this as a temporary dip before a larger rally driven by long-term AI growth. Concerns about valuation, market manipulation, and broader economic headwinds are also fueling the discussion.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending due to rising memory chip prices driven by AI data center demand, with some analysts predicting substantial future growth and a new price target. Community discussions reflect bullish sentiment, but also caution about potential pullbacks after a significant year-to-date increase. Some traders point to technical indicators suggesting it may be overbought in the short-term.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

MCRB is trending as the community speculates about a potential buyout, with many pointing to Nestle as a likely suitor given past collaborations and recent corporate restructuring. Discussions revolve around the timing of a deal before the end of the year, potential offer prices, and the impact on shareholders. Some traders are expressing skepticism, citing possible pump-and-dump schemes or an upcoming offering.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending due to positive community sentiment fueled by strong earnings and a potential shift to a tech-forward image with a possible move to the Nasdaq. Discussions also revolve around the impact of consumer spending habits, SNAP benefits, and competition with other retailers. The stock is experiencing increased interest and mentions as a key player in the retail sector.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending downwards, sparking debates about whether it's a temporary dip or the start of a longer bear market, as community members analyze support levels and potential bottom prices. Mixed opinions are fueled by discussions of market manipulation, external factors like potential strategic reserves, and comparisons to the performance of traditional markets. Some traders express concern over heavy liquidations, while others remain optimistic about long-term prospects and institutional adoption.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing significant volatility, driven by reactions to economic data and sector-specific news like NVDA's earnings. Community chatter highlights a struggle between bulls and bears, with many discussing potential bull traps and the impact of AI on the market. Traders are closely watching key support and resistance levels amid uncertainty about future rate cuts.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is experiencing significant volatility, with community discussions focused on potential downside risks and the correlation with Bitcoin's price movements. Bearish sentiment seems to be growing as some traders discuss shorting opportunities and question the company's long-term prospects given its leveraged position in Bitcoin. Others remain bullish, citing oversold conditions and potential for a rebound.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending amid volatile crypto markets and a recent downturn, leading to heightened community discussion around unrealized losses and potential bottom prices. Investors are closely watching for a potential announcement regarding staking rewards to support the stock's price, while also debating the influence of analysts like Tom Lee and market factors on BMNR's performance in relation to Ethereum.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as investors discuss a recent sell-off despite strong earnings, with community members debating whether this presents a buying opportunity or if concerns about profitability and guidance warrant caution. Some are concerned about Waymo and Tesla's presence in the autonomous vehicle space. Others cite low P/E and upcoming catalysts as reasons for bullish sentiment.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Buffett's Investing Lessons: What They Mean for ETF Investors

Buffett's final lessons guide ETF investors toward discipline, cash strength and quality picks like SPY, ITOT, VTV and MINT.

<ul class="summary-bullets"><li>4D-150 demonstrated consistent and durable benefits in patients with wet age-related macular degeneration in the study.&nbsp;</li><li>The company is currently enrolling patients into late-stage trials for the drug.</li><li>Enrollment is continuing ahead of initial projections, CEO David Kirn said. &nbsp;</li></ul>4D Molecular Therapeutics (FDMT) announced on Thursday that its experimental drug 4D-150 demonstrated consistent and durable benefits in patients with wet age-related macular degeneration in an early-to-mid-stage trial.Wet age-related macular degeneration (AMD) is an advanced form of macular degeneration where abnormal blood vessels grow in the retina, leak fluid or blood, and cause a rapid decline in central vision. The proliferation and leakage of abnormal blood vessels is stimulated by vascular endothelial growth factor (VEGF), a protein that promotes the growth of new blood vessels. According to 4D, the disease has a high incidence, with 200,000 individuals estimated to be newly diagnosed every year in the U.S. alone.<h2 class="st-heading-2">Study Findings</h2>4D-150 showed maintenance of visual acuity and control of retinal anatomy in the study, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-announces-positive-long-term-data-phase-12-prism-clinical">said</a>. The study also reduced treatment burden as patients maintained a consistent and clinically meaningful reduction in supplemental injections in 6-month intervals following dosing with 4D-150 through up to two years of follow-up, it added.4D-150 was further well tolerated with no new safety or intraocular inflammation findings. The drug is aimed at providing multi-year, and potentially lifelong, sustained delivery of anti-VEGF from the retina with a single, safe, intravitreal injection. Anti-VEGF is a treatment that blocks the action of the vascular endothelial growth factor.The company is currently enrolling patients into late-stage trials for the drug. Enrollment is continuing ahead of initial projections, according to CEO David Kirn.“With the robust PRISM dataset and our APAC region strategic partnership with Otsuka announced last week, we are well positioned for global success in our Phase 3 4FRONT clinical trials, which continue to enroll ahead of initial projections,” he added. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company soared 13% in the pre-market session at the time of writing. On Stocktwits, retail sentiment regarding <a href="https://stocktwits.com/symbol/FDMT">FDMT stock</a> remained within the ‘bullish’ territory, while message volume remained at ‘high’ levels over the past 24 hours.FDMT stock is up 89% this year and approximately 26% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dupont-announces-2-billion-share-buyback-stock-tumble-7-today/cL2t8hLREbz">DuPont Announces $2 Billion Share Buyback: Why Did The Stock Tumble 7% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

FDMT Stock Gains Pre-Market After Positive Study Data For Experimental Drug In Eye Disease

The drug showed maintenance of visual acuity, control of retinal anatomy, and reduction of treatment burden at all time points with up to 2 years of follow-up. 

Equity

The drug showed maintenance of visual acuity, control of retinal anatomy, and reduction of treatment burden at all time points with up to 2 years of follow-up. 


Payment services applications PayPal and Venmo were both down for some users in the United States&nbsp;on Thursday, according to Downdetector, which tracks real-time outages across thousands of websites, apps, and internet providers.Downdetector showed that 9,597 users in the United States were facing issues with PayPal at 12 p.m. ET, and 8,373 users were having outages on Venmo as of 11:47 a.m. ET.<figure class="image"><a class="st-link-external" href="https://downdetector.com/status/paypal/" target="_blank" rel="noopener noreferrer nofollow"><img style="aspect-ratio:951/588;" src="https://news.stocktwits-cdn.com/Pay_Pal_DD_png_e0280c5766.webp" alt="PayPal DD.png" width="951" height="588"></a></figure>Users on Stocktwits also noted issues regarding logging into PayPal.<stembedurl>https://stocktwits.com/ToRni27/message/632596267</stembedurl>According to Downdetector, 83% of users reported login issues for PayPal, while 10% noted payment-related issues and 6% purchase problems. Shares of PayPal were down nearly 3% in afternoon trading.For Venmo, Downdetector showed that 54% of the users were facing issues on the application and 8% on its website. Meanwhile, 38% reported login issues on Venmo, per Downdetector.<figure class="image"><a class="st-link-external" href="https://downdetector.com/status/venmo/" target="_blank" rel="noopener noreferrer nofollow"><img style="aspect-ratio:955/591;" src="https://news.stocktwits-cdn.com/Venmo_DD_png_721fc24224.webp" alt="Venmo DD.png" width="955" height="591"></a></figure>Venmo was bought by PayPal in 2013. Retail sentiment on PayPal dipped to ‘neutral’ from ‘bullish’ territory a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits.According to a PayPal spokesperson, both PayPal and Venmo experienced a brief service disruption, which has since been resolved.On Monday, Goldman Sachs analyst Will Nance downgraded PayPal to ‘Sell’ from ‘Neutral’ with a $70 price target, according to TheFly. The firm said it believes PayPal will face several transaction margin headwinds in 2026, including interest rate headwinds and the lapping of a reacceleration of its credit products.Goldman said it also sees less visibility for the company's branded checkout reacceleration in the near term, given softer trends in Germany, tariff disruptions in the U.S., and competing wallet form factors. <a href="https://stocktwits.com/symbol/PYPL">Shares of PayPal</a> have declined nearly 23% this year and have lost 17.5% of their value in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/apple-s-eddy-cue-pushes-for-fixing-sports-streaming-as-company-nears-formula-1-rights-deal/ch6pIQER3nx">Apple’s Eddy Cue Pushes For Fixing Sports Streaming As Company Nears Formula 1 Rights Deal</a>Editor's Note: The story has been updated with PayPal's statement regarding the service disruption.

In this photo illustration, a person holds a smartphone displaying the logo of PayPal Holdings Inc. 

Are PayPal, Venmo Down In The US? Here's What Downdetector Shows

Downdetector showed that 9,597 users in the United States were facing issues with PayPal at 12 pm ET, and 8,373 users were having outages on Venmo as of 11:47 am ET.

Shares of Roivant (ROIV) jumped 9% on Wednesday after the company, along with Priovant Therapeutics, announced positive results from a late-stage trial evaluating Brepocitinib in dermatomyositis.Dermatomyositis is a multi-organ idiopathic inflammatory condition that affects approximately 50,000 adults in the U.S. and is characterized by debilitating muscle weakness and skin lesions. No targeted therapies are approved for the condition, and a majority of patients are treated with high-dose oral steroids.Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study, including measurements of skin disease, muscle disease, steroid-sparing effect, and rapidity of onset, the company said.On Stocktwits, retail sentiment around ROIV stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:619/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_17_at_2_05_09_PM_png_94ffd6f84d.webp" alt="ROIV's Sentiment Meter and Message Volume as of 2:05 p.m. ET on Sept. 17, 2025 | Source: Stocktwits" width="619" height="61"><figcaption>ROIV's Sentiment Meter and Message Volume as of 2:05 p.m. ET on Sept. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism that the stock would rally further to $17.<stembedurl>https://stocktwits.com/StockBraker/message/628947861</stembedurl>Another user also cheered the stock’s rally over the past few weeks.<stembedurl>https://stocktwits.com/bbbloo/message/628950392</stembedurl>The company stated that 30mg of Brepocitinib achieved a week 52 mean Total Improvement Score (TIS) of 46.5 compared to 31.2 for placebo. It added that more than two-thirds of patients receiving the Brepocitinib 30 mg dose experienced at least a moderate response, with a TIS equal to or greater than 40, and nearly half experienced a major response, with a TIS equal to or exceeding 60.Furthermore, 42% of Brepocitinib 30 mg patients were able to discontinue steroids altogether, compared to 23% for the placebo, while 62% achieved a steroid dose of 2.5 mg or less per day. The safety profile observed in the study was consistent with that of previous trials, the company stated.The company plans to file for approval of the drug with the U.S. Food and Drug Administration for the treatment of dermatomyositis in the first half of 2026.ROIV stock is up 31% this year and approximately 28% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gm-in-talks-to-renew-jv-with-chinas-saic-report/chDGDTkRd6t">GM In Talks To Renew JV With China’s SAIC: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Roivant Sciences logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17

Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study, the company said. 

Dave &amp; Buster's Entertainment (PLAY) was among the top five losers on Stocktwits after multiple price target cuts from Wall Street following its second-quarter sales, which were pressured due to a difficult macro environment and challenges related to the brand.Shares of the company were down nearly 17% before the bell on Tuesday after Dave &amp; Buster’s <a href="https://stocktwits.com/news-articles/markets/equity/why-is-dave-and-busters-stock-plunging-premarket/chwyaxsRdyl">missed quarterly results</a>. UBS cut its price target on Dave &amp; Buster's to $25 from $29 and maintained a ‘Neutral’ rating, according to TheFly.The firm said that <a href="https://stocktwits.com/symbol/PLAY">Dave &amp; Buster's</a> second-quarter results included still pressured sales trends, likely given a difficult macro and brand-specific challenges, while margins and earnings were also depressed.UBS noted that while the company is still in the early stages of a turnaround, with macro pressure remaining elevated and visibility limited, an eventual return to consistently positive same-store sales represents potential upside for shares.The retail user message count on the stock jumped 5,200% in the last 24 hours on Stocktwits. Retail sentiment remained unchanged in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<figure class="image"><img style="aspect-ratio:792/102;" src="https://news.stocktwits-cdn.com/PLAY_sentiment_png_f0791affdf.webp" alt="PLAY sentiment.png" width="792" height="102"><figcaption>PLAY sentiment and message volume September 16, 2025, as of 8:10 am ET | Source: Stocktwits</figcaption></figure>Truist Securities cut its price target on Dave &amp; Buster's to $22 from $27 and maintained a ‘Hold’ rating. The firm said that the company's same-store sales decelerated in the back half of the quarter despite much easier year-ago compares as growing macro headwinds offset recent gains from its "back to basics" approach.Brokerage Truist Securities noted that while it sees incremental sales drivers in the second half of 2025, it also sees a risk that consumer pressures mount. Piper Sandler lowered its price target on Dave &amp; Buster's to $26 from $30 and maintained a ‘Neutral’ rating, according to TheFly.A bearish user on Stocktwits noted that there was “no upward catalyst” until the next earnings.<stembedurl>https://stocktwits.com/Bobky2030/message/628801944</stembedurl>Shares of Dave &amp; Buster’s have declined over 17% this year and lost nearly a quarter of its value in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/united-airlines-to-hire-2500-employees-at-newark-airport/chwyLDMRdzb">United Airlines To Hire 2,500 Employees At Newark Airport</a>

The exterior of a Dave & Buster's restaurant is seen on June 10, 2025 in Austin, Texas.

Dave & Buster’s Sees Wall Street Downgrades, Yet Retail Sentiment Red-Hot

UBS said that while Dave & Buster’s was still in the early stages of a turnaround, with macro pressure remaining elevated and visibility limited, an eventual return to consistently positive same-store sales represents potential upside for shares.

In this photo illustration, a smartphone held in a hand shows the logo of The Kroger Co. (NYSE: KR), a U.S. supermarket chain and one of the largest grocery retailers in the country.

Kroger Interim CEO Highlights Shift To Coupons, Private Labels Amid Economic Pressures: ‘Customers Are Feeling Stressed’

However, Ron Sargent also noted that Kroger was adding new households and growing order volumes with existing consumers who already shop with the grocer.

Centene Corporation (CNC) announced on Thursday that the company’s business and financial results through August are consistent with its full-year forecast.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001071739/000107173925000168/cnc-20250911.htm">said</a> in a filing with the U.S. Securities and Exchange Commission that members of its management will discuss the company’s financial results through August at the Deutsche Bank 2025 Healthcare Summit on Thursday. These results, it said, are consistent with the company’s outlook from the July second-quarter earnings call, which stated that it expects full-year adjusted and diluted earnings per share of $1.75.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CNC">CNC stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels. Shares of the company traded 10% higher at the time of writing.<figure class="image"><img style="aspect-ratio:576/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_11_29_55_AM_png_418f9b242e.webp" alt="CNC's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Sept. 11, 2025 | Source: Stocktwits" width="576" height="61"><figcaption>CNC's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Sept. 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sees the rally as the beginning of a recovery back to $50.<stembedurl>https://stocktwits.com/Hornito/message/628314829</stembedurl>Another user expressed optimism that the stock could reach as high as $70.<stembedurl>https://stocktwits.com/Zado148/message/628307192</stembedurl>“...the Medicaid results for July and August were supportive of the HBR (health benefit ratio) improvement trajectory that we're looking for in the back half of the year,” Centene CEO Sarah London said at the event, according to the transcript provided by Fiscal AI. She also added that the medicare segment continues to be on track for the roughly $700 million of improvement the company talked about in July.After the company’s second-quarter earnings fell below Wall Street estimates, London had <a href="https://stocktwits.com/news-articles/markets/equity/centene-reports-unexpected-q2-loss/chobP3PR5w5">said</a> in July that the company has a clear understanding of the trends that impacted its quarterly performance and is working with urgency to restore its earnings trajectory.CNC stock is down by 43% this year and by about 53% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wolfpack-research-reveals-short-position-in-faraday-future/chwNmHARdvm">Wolfpack Research Reveals Short Position In EV Maker Faraday Future</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a Centene Corporation logo seen displayed on a smartphone with the stock market information of Centene Corporation in the background. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Centene Stock Rises After Insurer Reaffirms Full-Year Guidance: Retail Sees Stock Rallying Up To $70

The company said that its July and August results are consistent with the company’s outlook from the July second-quarter earnings call.

Bumble (BMBL) CEO Wolfe Herd and team are reportedly building a new, AI-powered matchmaking app.The Wall Street Journal <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/tech/ai/whitney-wolfe-herd-bumble-ai-398779bb?mod&amp;#61;Searchresults&amp;pos&amp;#61;1&amp;page&amp;#61;1">reported</a> on Friday that Bumble has consulted psychologists and relationship counselors to program a matchmaking AI. The company plans to launch a beta version of the app to select users this fall, according to the report, which notes that it will be separate from the existing Bumble app.Shares of the company traded nearly 1% lower by Friday noon. On Stocktwits, retail sentiment about <a href="https://stocktwits.com/symbol/BMBL">BMBL stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.The goal behind the AI-powered matchmaking app is to create “the world’s smartest and most emotionally intelligent matchmaker in existence,” the report said, citing Herd. The new app aims to help users build a dating profile based on how they answer questions about past relationships, breakups, and experiences with love and dating, according to the report. It will be built as a large language model, communicating with users in a humanlike way.The team is unsure of how many matches the system will generate, and the monetization strategy is still being determined, the report said. However, users might also have to pay for each match, it said.Once it is ready, the new app will get to know the user over multiple sessions, make a dating profile for them, find them matches, and help book reservations for a date, the report said. BMBL stock is down 23% this year and approximately 5% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nukkleus-to-form-joint-venture-with-israel-based-mandragola/chtTmaPRdNN">Nukkleus Stock Shot Up A Whopping 37% Today – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

The exterior of Bumble Headquarters on July 15, 2024 in Austin, Texas. (Photo by Brandon Bell/Getty Images)

Bumble Developing AI-Powered Matchmaking App: Report

 According to The Wall Street Journal, the company plans to launch a beta version of the app to select users this fall, which will be separate from the existing Bumble app. 

Dynavax Technologies Corp. (DVAX) on Thursday said that its experimental Shingles vaccine yielded positive results in an early-to-mid-stage study as compared to GSK Plc’s (GSK) Shingrix vaccine. &nbsp;Herpes zoster, or shingles, is a viral infection that affects approximately one in three people in their lifetime. The disease is characterized by a painful rash and can lead to serious complications, particularly in older adults.The company evaluated the experimental vaccine in participants aged 50 to 69 years for the first part of the study, and it showed that at one month after the second vaccine dose, Z-1018 <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.dynavax.com/news-releases/news-release-details/dynavax-announces-positive-topline-phase-12-results-supporting">demonstrated</a> immune responses similar to those observed in the arm receiving Shingrix with a favorable tolerability profile.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/DVAX">DVAX stock</a> jumped from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels. Shares of the company traded 6% higher on Thursday afternoon at the time of writing.<figure class="image"><img style="aspect-ratio:569/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_21_at_2_08_19_PM_png_e38a9696ce.webp" alt="DVAX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Aug. 21, 2025 | Source: Stocktwits" width="569" height="59"><figcaption>DVAX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Aug. 21, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user suggested holding the stock patiently.<stembedurl>https://stocktwits.com/poorguy/message/626078462</stembedurl>The company said that it now intends to advance Z-1018 into the next part of the study in adults 70 years of age and older in the second half of the year. At the dose formulation and regimen chosen for advancing to the next part of the trial, Z-1018 achieved 100% antibody production compared to Shingrix at 96.9%, the company said.Furthermore, only 12.5% of participants receiving Z-1018 at the dose reported local post-injection reactions, compared to 52.6% for Shingrix, the company said. It also noted that 27.5% participants reported body-wide reactions with the experimental vaccine, compared to 63.2% in Shingrix."These positive data mark an important inflection point for our novel shingles vaccine program as we strive to develop a product with a potential best-in-class profile with the aim to disrupt the multi-billion-dollar shingles vaccine market, which is currently dominated by one product," said CEO Ryan Spencer, referring to Shingrix.DVAX stock is down by 14% this year and by about 3% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nio-unveils-new-es8-starting-at-rmb-416800/chsj2ghRdiq">Nio Stock Rocketed 10% Today And Retail Believes It Could Hit The $10-Mark By Earnings – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medical syringe is seen with Dynavax company logo displayed on a screen in the background in this illustration photo taken in Poland on June 16, 2020. (Photo Illustration by Jakub Porzycki/NurPhoto via Getty Images)

Dynavax’s Experimental Shingles Vaccine Shows Positive Results In Study: Retail Expects Stock Rally To Continue Into Friday

The company said that it now intends to advance Z-1018 into the next part of the study in adults 70 years of age and older in the second half of the year.

Barclays has initiated coverage of Incyte (INCY) with an ‘Overweight’ rating and a $90 price target on Friday.The price target implies an over 20% upside to the stock’s closing price on Thursday.&nbsp;Shares of the company traded about 0.4% higher on Friday afternoon at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/INCY">INCY</a> trended in the ‘bullish’ territory, accompanied by ‘high’ message volume.<figure class="image"><img style="aspect-ratio:1332/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_01_at_2_26_04_PM_png_30d60d7ced.webp" alt="INCY's Sentiment Meter and Message Volume as of 2:25 p.m. ET on Aug. 1, 2025 | Source: Stocktwits" width="1332" height="126"><figcaption>INCY's Sentiment Meter and Message Volume as of 2:25 p.m. ET on Aug. 1, 2025 | Source: Stocktwits</figcaption></figure>The firm said that it sees "value-inflecting" data readouts for the pharmaceutical company in the second half of 2025 and 2026.It believes the pivotal data for Tafasitamab in diffuse large B-cell lymphoma and the mid-stage data for Povorcitinib in chronic spontaneous urticaria patients provide the next legs of growth for Incyte.Earlier this week, Incyte said during its second-quarter earnings that it now expects late-stage data from the study evaluating Tafasitamab as a first-line treatment for diffuse large B-cell lymphoma by the second half of 2025. Incyte is now focusing on its development pipeline as its cancer drug, Jakafi, nears patent expiration.“Continued progress and diversification of our portfolio, including advancements with povorcitinib and mutCALR, are strengthening the foundation for sustainable, long-term growth,” CEO Bill Meury said.Jakafi net revenue came in at $764 million in the second quarter of the year, marking a growth of 8% year-on-year, and accounting for about 63% of the company’s total revenue in the quarter of $1.216 billion, which surpassed Wall Street expectations. &nbsp;For the full year, the company is eyeing revenue of $3 billion to $3.5 billion from Jakafi.Another important drug from the company is its Opzelura cream, used to treat nonsegmental vitiligo, which brought in revenues of $164 million in the second quarter, marking a growth of 35% year-on-year.Overall, for the second quarter, the company reported an adjusted and diluted earnings per share of $1.57, compared to a loss per share of $1.82 reported in the corresponding period of 2024.According to data from Koyfin, 11 of 27 analysts covering the stock rate it ‘Buy’ or higher, while 15 rate it ‘Hold’, and just one rates it a ‘Sell’. The average price target on the stock is $79.87, representing an upside of about 6% from the current price.The stock is up by over 9% this year and by about 17% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pheton-holdings-dismisses-rumors-of-acquisition-by-gilead/chrEENyRdRR">Pheton Holdings Dismisses Rumors Of Acquisition By Gilead, But Retail’s Extremely Optimistic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Barclays Initiates Incyte With Overweight Rating, $90 Price Target, Retail Finds Reason To Cheer 

Barclays sees "value-inflecting" data readouts for the pharmaceutical company in the second half of 2025 and 2026.

Current Price	$128.34
Prev Close	$127.26
Open	$128.51
Dividend Yield	N/A
50-Day Moving Average	$131.09
Beta	N/A
Avg. Volume	29,421.13
PE Ratio	N/A

52-Week High	$134.95
52-Week Low	$96.10
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

PKW
Invesco BuyBack Achievers ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PKW News

PKWInvesco BuyBack Achievers ETF